Celcuity Inc.

NasdaqCM:CELC Stock Report

Market Cap: US$489.7m

Celcuity Management

Management criteria checks 4/4

Celcuity's CEO is Brian Sullivan, appointed in Jan 2012, has a tenure of 12.83 years. total yearly compensation is $1.74M, comprised of 12.1% salary and 87.9% bonuses, including company stock and options. directly owns 8.12% of the company’s shares, worth $39.79M. The average tenure of the management team and the board of directors is 3.8 years and 9.3 years respectively.

Key information

Brian Sullivan

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage12.1%
CEO tenure12.8yrs
CEO ownership8.1%
Management average tenure3.8yrs
Board average tenure9.3yrs

Recent management updates

Recent updates

Celcuity: Breast Cancer Drug Developer With Upcoming Catalysts

Nov 06

Is Celcuity (NASDAQ:CELC) Using Too Much Debt?

Aug 31
Is Celcuity (NASDAQ:CELC) Using Too Much Debt?

Celcuity: Flying A Phase 3 Trial Right Under Your Nose

Jul 05

Does Celcuity (NASDAQ:CELC) Have A Healthy Balance Sheet?

May 08
Does Celcuity (NASDAQ:CELC) Have A Healthy Balance Sheet?

Is Celcuity (NASDAQ:CELC) Using Too Much Debt?

Jul 04
Is Celcuity (NASDAQ:CELC) Using Too Much Debt?

Is Celcuity (NASDAQ:CELC) A Risky Investment?

Sep 13
Is Celcuity (NASDAQ:CELC) A Risky Investment?

Celcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment

Jul 18

Is Celcuity (NASDAQ:CELC) A Risky Investment?

Jan 27
Is Celcuity (NASDAQ:CELC) A Risky Investment?

Health Check: How Prudently Does Celcuity (NASDAQ:CELC) Use Debt?

Sep 21
Health Check: How Prudently Does Celcuity (NASDAQ:CELC) Use Debt?

Celcuity: Nipping The Oncogenic Bud

Jul 08

What You Need To Know About Celcuity Inc.'s (NASDAQ:CELC) Investor Composition

Mar 14
What You Need To Know About Celcuity Inc.'s (NASDAQ:CELC) Investor Composition

We're Hopeful That Celcuity (NASDAQ:CELC) Will Use Its Cash Wisely

Jan 20
We're Hopeful That Celcuity (NASDAQ:CELC) Will Use Its Cash Wisely

Celcuity inks clinical trial pact with Massachusetts General Hospital and Puma Technologies

Dec 23

Could The Celcuity Inc. (NASDAQ:CELC) Ownership Structure Tell Us Something Useful?

Nov 29
Could The Celcuity Inc. (NASDAQ:CELC) Ownership Structure Tell Us Something Useful?

Celcuity EPS beats by $0.03

Nov 09

CEO Compensation Analysis

How has Brian Sullivan's remuneration changed compared to Celcuity's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$94m

Jun 30 2024n/an/a

-US$83m

Mar 31 2024n/an/a

-US$73m

Dec 31 2023US$2mUS$210k

-US$64m

Sep 30 2023n/an/a

-US$57m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$2mUS$106k

-US$41m

Sep 30 2022n/an/a

-US$36m

Jun 30 2022n/an/a

-US$31m

Mar 31 2022n/an/a

-US$35m

Dec 31 2021US$1mUS$260k

-US$30m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$22m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$469kUS$250k

-US$9m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$8m

Mar 31 2020n/an/a

-US$8m

Dec 31 2019US$992kUS$250k

-US$7m

Sep 30 2019n/an/a

-US$7m

Jun 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$7m

Dec 31 2018US$564kUS$250k

-US$7m

Sep 30 2018n/an/a

-US$7m

Jun 30 2018n/an/a

-US$7m

Mar 31 2018n/an/a

-US$7m

Dec 31 2017US$490kUS$232k

-US$6m

Compensation vs Market: Brian's total compensation ($USD1.74M) is about average for companies of similar size in the US market ($USD2.14M).

Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.

CEO

Brian Sullivan (62 yo)

12.8yrs

Tenure

US$1,738,115

Compensation

Mr. Brian F. Sullivan is the Co-Founder of Celcuity Inc. and has been its Chairman and Chief Executive Officer since 2012 and served as its Chief Financial Officer. Mr. Sullivan Co-founded Entegris, Inc. i...

Leadership Team

NamePositionTenureCompensationOwnership
Brian Sullivan
Co-Founder12.8yrsUS$1.74m8.12%
$ 39.8m
Lance Laing
Co-Founder12.8yrsUS$1.48m3.37%
$ 16.5m
Vicky Hahne
Chief Financial Officer7.3yrsUS$898.74k0.050%
$ 244.8k
Brent Eilefson
General Counselless than a yearno datano data
John MacDonald
Senior Vice President of R&D3.8yrsno datano data
Sheri Smith
Acting Head of Clinical Operations3.8yrsno datano data
Igor Gorbatchevsky
Chief Medical Officer2.7yrsno datano data
Eldon Mayer
Chief Commercial Officerless than a yearno datano data
Charlotte Moser
Senior Vice President of Clinical Developmentless than a yearno datano data

3.8yrs

Average Tenure

62yo

Average Age

Experienced Management: CELC's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brian Sullivan
Co-Founder12.8yrsUS$1.74m8.12%
$ 39.8m
Lance Laing
Co-Founder12.8yrsUS$1.48m3.37%
$ 16.5m
Richard Nigon
Independent Director7.8yrsUS$87.50k0.27%
$ 1.3m
David Dalvey
Independent Director10.8yrsUS$87.50k0.025%
$ 123.0k
Leo Furcht
Independent Director5.5yrsUS$87.50k0.028%
$ 138.5k
Ronald McGlennen
Member of Scientific Advisory Boardno datano datano data
Edward Greeno
Member of Scientific Advisory Boardno datano datano data
Sara A. Hurvitz
Member of Scientific Advisory Boardno datano datano data
Carol Lange
Member of Scientific Advisory Boardno datano datano data
Benita Katzenellenbogen
Member of Scientific Advisory Boardno datano datano data
John Katzenellenbogen
Member of Scientific Advisory Boardno datano datano data
Mothaffar Rimawi
Member of Scientific Advisory Board5.8yrsno datano data

9.3yrs

Average Tenure

66yo

Average Age

Experienced Board: CELC's board of directors are considered experienced (9.3 years average tenure).